Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.

With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced therapeutics. Bharat has unveiled plans to set up its first cell and gene ...

Successful program buildout prioritizes defined patient flow, infusion access, cold-chain capabilities, and accountability ...

Q4 2025 earnings call recap: revenue beat, 2026 guidance $190–$194M, cell & gene therapy growth, EBITDA outlook—read now.

Delaying onboarding until FDA approval reduces sunk-cost risk but can impede institutional learning and slow post-approval ...

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decision ...

Cell and gene therapies, or CGT, have come a long way since they were first introduced. In the last few decades, both cell therapy -- the transplantation of living cells -- and gene therapy -- the use ...

Cell and gene therapies (CGTs) are gaining strategic importance across the healthcare landscape, with oncology being the leading therapeutic area followed by cardiovascular and central nervous system ...

Despite innovative new research, many cell and gene therapies do not make it all the way to the patients. Researchers and clinicians in Lund have now presented a new model for cooperation that will ...

A new research project at the Cyprus Institute of Neurology and Genetics (CING) aims to develop a one-time, curative therapy for beta-thalassemia, the most common inherited blood disorder in Cyprus.